Dynavax Technologies Corporation or Galapagos NV: Who Invests More in Innovation?

Biotech Giants' R&D Race: Galapagos vs. Dynavax

__timestampDynavax Technologies CorporationGalapagos NV
Wednesday, January 1, 201484580000111110000
Thursday, January 1, 201586943000129714000
Friday, January 1, 201684493000139574000
Sunday, January 1, 201764988000218502000
Monday, January 1, 201874951000322876000
Tuesday, January 1, 201962331000427320000
Wednesday, January 1, 202028607000523667000
Friday, January 1, 202132228000491707000
Saturday, January 1, 202246600000515083000
Sunday, January 1, 202354886000241294000
Loading chart...

Unleashing insights

Innovation Investment: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Dynavax Technologies Corporation and Galapagos NV have been at the forefront of this race, each investing heavily in research and development (R&D). From 2014 to 2023, Galapagos NV consistently outpaced Dynavax, with R&D expenses peaking at over 500% higher than Dynavax's lowest investment year. Notably, in 2020, Galapagos NV's R&D spending reached its zenith, more than doubling Dynavax's expenditure. However, Dynavax showed resilience, increasing its R&D investment by nearly 92% from its lowest point in 2020 to 2023. This strategic focus on innovation underscores the dynamic nature of the biotech industry, where companies must continuously adapt and invest to maintain a competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025